GlobeNewswire Inc | Jan 7, 2021 08:30AM EST

January 07, 2021

BOSTON, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced that it will host a virtual Commercial Day for investors on February 11 from 11:30-1:00pm EST.

Presentations will include an overview of the long-term corporate strategy, the global market opportunity in rare pediatric and adult liver disease, and the global commercialization strategy and launch readiness plans for odevixibat in progressive familial intrahepatic cholestasis (PFIC), an ultra-rare pediatric cholestatic liver disease.

The event will be hosted by Ron Cooper, President and Chief Executive Officer and members of Albireo leadership.

Commercial Day Call Details for Thursday, February 11 from 11:30-1:00pm ESTDomestic: 1-877-407-0792International 1-201-689-8263Conference ID: 13714756Participant Webcast Link: http://public.viavid.com/index.php?id=142919

The virtual event will also be accessible from the Albireo Media and Investors page ir.albireopharma.com.

About AlbireoAlbireo Pharmais a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases, and other adult liver diseases and disorders. Albireos lead product candidate, odevixibat, is being developed to treat rare pediatric cholestatic liver diseases with Phase 3 pivotal trials in PFIC, Alagille syndrome and biliary atresia. The Company completed IND-enabling studies for new preclinical candidate A3907 this year and plans to advance development in adult liver disease. Albireo was spun out from AstraZenecain 2008 and is headquartered inBoston,Massachusetts, with its key operating subsidiary inGothenburg,Sweden. TheBoston Business Journalnamed Albireo one of the 2020 Best Places to Work inMassachusetts for the second consecutive year. For more information on Albireo, please visitwww.albireopharma.com.

Media & Investor contacts:Colleen Alabiso, 857-356-3905, colleen.alabiso@albireopharma.comHans Vitzthum, LifeSci Advisors, LLC., 617-430-7578